CUMULATED SALES
as of December 31st, 2016
€18.5 M
+33%
Investors
Investors
The SpineJack® is becoming a standard for the treatment of vertebral fractures and VEXIM’s technology has been embraced by several key opinion leaders. We can already confirm we have reached the milestone of 40,000 implants sold – which represents approximatively more than 20,000 patients.
We will build on this success and on our leading technology platform to extend our product offering and target new pathologies in spine trauma by 2018.
LIVE STOCK QUOTE
EPA:
08 Mar - 00:11 UTC+00:00
Eur ↑ (0%)
VEXIM shows great opportunities
and now heads towards autonomy
and financial independence.
FINANCIAL KEY FIGURES
as of December 31st, 2016
€18.5 M
+33%
as of December 31st, 2016
€13.4 M
+72.2% of sales
as of December 31st, 2016
€9.8 M
FINANCIAL KEY FIGURES
as of December 31st, 2016
€18.5 M
+33%
as of December 31st, 2016
€13.4 M
+72.2% of sales
as of December 31st, 2016
€9.8 M